Основная статистика
| LEI | 549300LDT5AP8S0NBM78 |
| CIK | 1167379 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Alcon Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 19, 2025 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 9 Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) Consolidated Income Statement 12 Consolidated Statement of Comprehensive Income 13 Consolidated Balance Sheet 14 Consolidated Statement of Changes in Equity 15 Consolidated Statement of Cash Flows 16 Notes to Condense |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 19, 2025 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registran |
|
| August 19, 2025 |
Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical •Second-quarter 2025 sales of $2. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☑ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 5, 2025 |
Alcon Agrees to Acquire STAAR Surgical Alcon Agrees to Acquire STAAR Surgical •STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes •Acquisition of STAAR is complementary to Alcon’s laser vision correction business and is expected to be accretive in year two •Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 5, 2025 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701, Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registran |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 28, 2025 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701, Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant |
|
| May 28, 2025 |
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease •In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 11-2 •TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease (DED)3 •Approximately 38 |
|
| May 28, 2025 |
Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2024 Exhibit 1.01 Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2024 Overview This Conflict Minerals Report for Alcon Inc. and its consolidated subsidiaries covers calendar year 2024 and was prepared in accordance with Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Rule 13p-1 under the Securities Exchange Act of 1934 (collectively, th |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Alcon Inc. (Exact name of the registrant as specified in its charter) Switzerland 001-31269 (State or other jurisdiction of incorporation or organization) (Commission File Number) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive offices) Royce Bedward Senior |
|
| May 13, 2025 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 7 Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) Consolidated Income Statement 10 Consolidated Statement of Comprehensive Income 11 Consolidated Balance Sheet 12 Consolidated Statement of Changes in Equity 13 Consolidated Statement of Cash Flows 14 Notes to Condense |
|
| May 13, 2025 |
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS •First-quarter 2025 sales of $2. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 13, 2025 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant f |
|
| April 4, 2025 |
Alcon Publishes Agenda for 2025 Annual General Meeting Alcon Publishes Agenda for 2025 Annual General Meeting •Alcon welcomes its shareholders to its third in-person AGM •Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member •Proposed dividend of CHF 0. |
|
| April 4, 2025 |
Agenda and Proposals of the Board of Directors Agenda and Proposals of the Board of Directors 1.Approval of the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2024 Proposal The Board of Directors proposes that the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2024 |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 4, 2025 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701, Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant |
|
| March 24, 2025 |
DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party Other than the Registrant ☒ Check the Appropriate Box ☐ Preliminary Proxy Statement ☐ Confidential for Use of the Commission only (as permitted by Rule 14a-6(e)(2)). |
|
| February 25, 2025 |
Exhibit 12.1 Certification of CEO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David J. Endicott, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessar |
|
| February 25, 2025 |
Exhibit 12.2 Certification of CFO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Timothy C. Stonesifer, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece |
|
| February 25, 2025 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2024 Alcon Inc. |
|
| February 25, 2025 |
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation •Full-year 2024 sales of $9. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 25, 2025 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 25, 2025 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| February 25, 2025 |
Certification of CFO Pursuant to 18 U.S.C. Section 1350 Exhibit 13.2 Certification of CFO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), full |
|
| February 25, 2025 |
1.PURPOSE Alcon Inc. and its affiliates (“Alcon”) are committed to complying with laws and regulations, including securities laws that prohibit “insider trading,” and to financial integrity. The purpose of this policy is to set out the: –Basic obligations of all Associates in possession of Material Non-Public Information, and –Additional obligations of Associates who have greater access to Materia |
|
| February 25, 2025 |
Letter from the Board Chair To Our Shareholders, As I reflect on 2024, it is clear that we have made notable progress while successfully navigating through multiple challenges. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring the shell company report Commission file number: 001-31269 Alcon Inc. |
|
| February 25, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. |
|
| February 25, 2025 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) Consolidated Income Statement 14 Consolidated Statement of Comprehensive Income 15 Consolidated Balance Sheet 16 Consolidated Statement of Changes in Equity 17 Consolidated Statement of Cash Flows 18 Notes to Condens |
|
| February 25, 2025 |
Certification of CEO Pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 Certification of CEO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), full |
|
| November 12, 2024 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) Consolidated Income Statement 14 Consolidated Statement of Comprehensive Income 15 Consolidated Balance Sheet 16 Consolidated Statement of Changes in Equity 17 Consolidated Statement of Cash Flows 18 Notes to Condens |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 12, 2024 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| November 12, 2024 |
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation •Third-quarter 2024 sales of $2. |
|
| August 20, 2024 |
Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses •Record Q2 2024 sales of $2. |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 20, 2024 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registran |
|
| August 20, 2024 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) Consolidated Income Statement 14 Consolidated Statement of Comprehensive Income 15 Consolidated Balance Sheet 16 Consolidated Statement of Changes in Equity 17 Consolidated Statement of Cash Flows 18 Notes to Condens |
|
| June 24, 2024 |
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U. |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 24, 2024 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701, Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant |
|
| May 29, 2024 |
Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2023 Exhibit 1.01 Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2023 Overview This Conflict Minerals Report for Alcon Inc. and its consolidated subsidiaries covers calendar year 2023 and was prepared in accordance with Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Rule 13p-1 under the Securities Exchange Act of 1934 (collectively, th |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Alcon Inc. (Exact name of the registrant as specified in its charter) Switzerland 001-31269 (State or other jurisdiction of incorporation or organization) (Commission File Number) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive offices) Royce Bedward Senior |
|
| May 13, 2024 |
Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health •First-quarter 2024 sales of $2. |
|
| May 13, 2024 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 8 Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) Consolidated Income Statement 11 Consolidated Statement of Comprehensive Income 12 Consolidated Balance Sheet 13 Consolidated Statement of Changes in Equity 14 Consolidated Statement of Cash Flows 15 Notes to Condense |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 13, 2024 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant f |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 7, 2024 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701, Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant |
|
| April 8, 2024 |
Agenda and Proposals of the Board of Directors Agenda and Proposals of the Board of Directors 1.Approval of the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2023 Proposal The Board of Directors proposes that the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2023 |
|
| April 8, 2024 |
Alcon Publishes Agenda for 2024 Annual General Meeting •Alcon welcomes its shareholders to its second in-person AGM •In addition to the regular agenda items, shareholders to vote on the Report on Non-Financial Matters •Proposed dividend of CHF 0. |
|
| February 27, 2024 |
Regulations of the Board of Directors, its Committees and the Executive Committee of Alcon Inc. 4 Regulations of the Board of Directors, its Committees and the Executive Committee of Alcon Inc. |
|
| February 27, 2024 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) Consolidated Income Statement 15 Consolidated Statement of Comprehensive Income/(Loss) 16 Consolidated Balance Sheet 17 Consolidated Statement of Changes in Equity 18 Consolidated Statement of Cash Flows 19 Notes to |
|
| February 27, 2024 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2023 Alcon Inc. |
|
| February 27, 2024 |
Exhibit 12.1 Certification of CEO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David J. Endicott, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessar |
|
| February 27, 2024 |
1 | Articles of Incorporation of Alcon Inc. | May 5, 2023 1 | Articles of Incorporation of Alcon Inc. | May 5, 2023 Section 1 Corporate Name, Registered Office, Purpose and Duration 3 Section 2 Share Capital 4 Section 3 Corporate Bodies 11 A. General Meeting of Shareholder 11 B. Board of Directors 16 C. Auditors 21 Section 4 Compensation of the Board of Directors and the Executive Committee 27 Section 5 Annual Financial Statements, Consolidated Financial |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 27, 2024 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| February 27, 2024 |
ALCON INC. POLICY FOR COMPENSATION RECOVERY IN THE EVENT OF A FINANCIAL RESTATEMENT (Adopted and approved on August 10, 2023 and effective as of October 2, 2023) 1.Purpose and Limitation Alcon Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 27, 2024 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| February 27, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-230794) of Alcon Inc. of our report dated February 27, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F. /s/ PricewaterhouseCoopers LL |
|
| February 27, 2024 |
Certification of CEO Pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 Certification of CEO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), full |
|
| February 27, 2024 |
Certification of CFO Pursuant to 18 U.S.C. Section 1350 Exhibit 13.2 Certification of CFO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), full |
|
| February 27, 2024 |
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023 •Q4 2023 sales of $2. |
|
| February 27, 2024 |
Exhibit 12.2 Certification of CFO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Timothy C. Stonesifer, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring the shell company report Commission file number: 001-31269 Alcon Inc. |
|
| February 27, 2024 |
Alcon is the global leader in eye care dedicated to helping people See Brilliantly. |
|
| November 14, 2023 |
ALCON INC. INTERIM FINANCIAL REPORT ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) Consolidated Income Statement 14 Consolidated Statement of Comprehensive Income 15 Consolidated Balance Sheet 16 Consolidated Statement of Changes in Equity 17 Consolidated Statement of Cash Flows 18 Notes to Condens |
|
| November 14, 2023 |
Three months ended September 30 Alcon Reports Third Quarter 2023 Results •Third quarter 2023 sales of $2.3 billion, up 8%, or 9% constant currency(1) (cc) •Third quarter 2023 diluted EPS of $0.41, up 78%, or up 97% cc; core diluted EPS(2) of $0.66 up 32%, or 41% cc •Generated $937 million of cash from operating activities and $592 million of free cash flow(3) in the first nine months of 2023 Ad Hoc Announcement Pursuant to Art. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 14, 2023 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 15, 2023 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registran |
|
| August 15, 2023 |
Alcon Reports Second Quarter 2023 Results Alcon Reports Second Quarter 2023 Results •Second quarter 2023 sales of $2.4 billion, up 9%, or 12% constant currency(1) (cc) •Second quarter 2023 diluted EPS of $0.34, up 13%, or up 34% cc; core diluted EPS(2) of $0.69 up 10%, or 19% cc •Based on strong operational performance and improved outlook, Company raises full year 2023 sales and core diluted EPS guidance Ad Hoc Announcement Pursuant to A |
|
| August 15, 2023 |
ALCON INC. INTERIM FINANCIAL REPORT ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 14 Consolidated Statement of Comprehensive Income 15 Consolidated Balance Sheet 16 Consolidated Statement of Changes in Equity 17 Consolidated Statement of Cash Flows 18 Notes to Condensed Consolidate |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Alcon Inc. (Exact name of the registrant as specified in its charter) Switzerland 001-31269 (State or other jurisdiction of incorporation or organization) (Commission File Number) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive offices) Royce Bedward Senior |
|
| May 30, 2023 |
Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2022 Exhibit 1.01 Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2022 Overview This Conflict Minerals Report for Alcon Inc. and its consolidated subsidiaries covers calendar year 2022 and was prepared in accordance with Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Rule 13p-1 under the Securities Exchange Act of 1934 (collectively, th |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 9, 2023 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant fi |
|
| May 9, 2023 |
Alcon Reports First Quarter 2023 Results •First quarter 2023 sales of $2.3 billion, up 7%, or 11% constant currency(1) (cc) •First quarter 2023 diluted EPS of $0.35, up 3%, or up 26% cc; core diluted EPS(2) of $0.70 up 3%, or 14% cc •Dividend of CHF 0.21 per share approved by shareholders at the Annual General Meeting on May 5, 2023 •Raised full year 2023 cc sales and core diluted EPS growth outlo |
|
| May 9, 2023 |
ALCON INC. INTERIM FINANCIAL REPORT ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 8 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 11 Consolidated Statement of Comprehensive Income 12 Consolidated Balance Sheet 13 Consolidated Statement of Changes in Equity 14 Consolidated Statement of Cash Flows 15 Notes to Condensed Consolidated |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 29, 2023 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701, Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registran |
|
| March 30, 2023 |
Agenda and Proposals of the Board of Directors Agenda and Proposals of the Board of Directors 1.Approval of the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2022 Proposal The Board of Directors proposes that the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2022 |
|
| March 30, 2023 |
Alcon Publishes Agenda for 2023 Annual General Meeting •Alcon welcomes its shareholders to its first in-person AGM •In addition to the regular agenda items, Alcon Board of Directors proposes to amend the Articles of Incorporation to conform to recent Swiss corporate law reform •Proposed dividend of CHF 0. |
|
| February 27, 2023 |
Exhibit 13.2 Certification of CFO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), full |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 27, 2023 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| February 27, 2023 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2022 Alcon Inc. |
|
| February 27, 2023 |
Consent of PricewaterhouseCoopers LLP CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. |
|
| February 27, 2023 |
, as Guarantor, and Citibank, N.A., as Trustee, EXECUTION VERSION INDENTURE SEPTEMBER 23, 2019 Among Alcon Finance Corporation as Company Alcon Inc. |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring the shell company report Commission file number: 001-31269 Alcon Inc. |
|
| February 27, 2023 |
ALCON INC. INTERIM FINANCIAL REPORT ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 15 Consolidated Statement of Comprehensive (Loss)/Income 16 Consolidated Balance Sheet 17 Consolidated Statement of Changes in Equity 18 Consolidated Statement of Cash Flows 19 Notes to Condensed Cons |
|
| February 27, 2023 |
Exhibit 4.19 AGREEMENT AND PLAN OF MERGER among AERIE PHARMACEUTICALS, INC., a Delaware corporation, ALCON RESEARCH, LLC, a Delaware limited liability company, and LYON MERGER SUB, INC., a Delaware corporation, Dated as of August 22, 2022 Table of Contents Section 1 The Merger 1.1 The Closing 1 1.2 The Merger 2 1.3 Conversion of Shares 2 1.4 Surrender of Certificates; Stock Transfer Books 3 1.5 Di |
|
| February 27, 2023 |
Alcon Reports Fourth Quarter and Full Year 2022 Results Alcon Reports Fourth Quarter and Full Year 2022 Results •Fourth quarter 2022 sales of $2. |
|
| February 27, 2023 |
Exhibit 13.1 Certification of CEO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), full |
|
| February 27, 2023 |
Exhibit 12.1 Certification of CEO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David J. Endicott, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessar |
|
| February 27, 2023 |
Alcon is the global leader in eye care, dedicated to helping people See Brilliantly. |
|
| February 27, 2023 |
Exhibit 12.2 Certification of CFO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Timothy C. Stonesifer, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 27, 2023 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| February 13, 2023 |
Alcon Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices Ad Hoc Announcement Pursuant to Art. |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 13, 2023 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701, Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the regist |
|
| February 10, 2023 |
CH:ALC / Alcon Inc / WCM INVESTMENT MANAGEMENT, LLC - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alcon Inc. (Name of Issuer) Common (Title of Class of Securities) H01301128 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| November 15, 2022 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 15 Consolidated Statement of Comprehensive Income/(Loss) 16 Consolidated Balance Sheet 17 Consolidated Statement of Changes in Equity 18 Consolidated Statement of Cash Flows 19 Notes to Condensed Cons |
|
| November 15, 2022 |
Alcon Reports Third Quarter 2022 Results Alcon Reports Third Quarter 2022 Results ?Third quarter 2022 sales of $2.1 billion, up 2%, or 9% constant currency (cc) ?Third quarter 2022 earnings were $0.23 per diluted share; core earnings of $0.50 per diluted share, down 7%, or up 14% cc ?Updated 2022 outlook reflects strong sales growth and operational leverage, negatively impacted by strong US dollar Ad Hoc Announcement Pursuant to Art. 53 |
|
| November 15, 2022 |
6-K 1 form6-kxearningsreleaseand.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 15, 2022 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) I |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 23, 2022 |
MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG Exhibit 99.1 MEDIA RELEASE ? COMMUNIQUE AUX MEDIAS ? MEDIENMITTEILUNG Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio ? Builds on Alcon?s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 ? Adds Rocklatan? and Rhopressa?, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical pr |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 22, 2022 Commission File Number: 001-31269 ALCON INC. |
|
| August 9, 2022 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 10 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 13 Consolidated Statement of Comprehensive Income 14 Consolidated Balance Sheet 15 Consolidated Statement of Changes in Equity 16 Consolidated Statement of Cash Flows 17 Notes to Condensed Consolidate |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 9, 2022 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant |
|
| August 9, 2022 |
Alcon Reports Second Quarter 2022 Results Alcon Reports Second Quarter 2022 Results ?Strong second quarter sales of $2.2 billion, up 5%, or 10% constant currency (cc) ?Second quarter earnings of $0.30 per diluted share, down 3%, or up 34% cc ?Second quarter core earnings of $0.63 per diluted share, up 13%, or 30% cc ?Updated 2022 full year outlook reflects strong underlying operational performance, impacted by strength of US dollar Ad Hoc |
|
| May 26, 2022 |
Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2021 EX-1.01 2 conflictmineralsreport31de.htm EX-1.01 Exhibit 1.01 Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2021 Overview This Conflict Minerals Report for Alcon Inc. and its consolidated subsidiaries covers calendar year 2021 and was prepared in accordance with Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Rule 13p-1 under the |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Alcon Inc. (Exact name of the registrant as specified in its charter) Switzerland 001-31269 (State or other jurisdiction of incorporation or organization) (Commission File Number) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive offices) Royce Bedward Senior |
|
| May 10, 2022 |
Alcon Reports First Quarter 2022 Results Alcon Reports First Quarter 2022 Results ?Strong quarterly sales of $2.2 billion, up 14% or 18% constant currency ?Double-digit growth in net sales in both Surgical and Vision Care ?Updated 2022 full year outlook Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, May 10, 2022 - Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the first quarter ended March 31, |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 10, 2022 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant f |
|
| May 10, 2022 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 8 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 11 Consolidated Statement of Comprehensive Income 12 Consolidated Balance Sheet 13 Consolidated Statement of Changes in Equity 14 Consolidated Statement of Cash Flows 15 Notes to Condensed Consolidated |
|
| March 24, 2022 |
IMPORTANT INFORMATION RELATING TO COVID-19 PANDEMIC IMPORTANT INFORMATION RELATING TO COVID-19 PANDEMIC Dear Shareholders, As a result of the continuing tense situation due to the coronavirus (COVID-19) pandemic, and as a precautionary and prudent measure, the Board of Directors decided that the 2022 Annual General Meeting will again be held without the personal attendance of shareholders and you will not be granted access to the meeting room, in accordance with the Federal Act on the statutory principles for Federal Council Ordinances on combating the COVID-19 epidemic and the Ordinance 3 of the Swiss Federal Council regarding measures to combat the COVID-19, both as amended (COVID-19 Regulations). |
|
| March 24, 2022 |
Alcon Publishes Agenda for 2022 Annual General Meeting ?Alcon Board of Directors proposes to elect Raquel C. |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 24, 2022 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701, Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registran |
|
| February 15, 2022 |
Exhibit 12.2 Certification of CFO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Timothy C. Stonesifer, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece |
|
| February 15, 2022 |
Exhibit 13.2 Certification of CFO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), full |
|
| February 15, 2022 |
Exhibit 13.1 Certification of CEO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), full |
|
| February 15, 2022 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 14 Consolidated Statement of Comprehensive Income/(Loss) 15 Consolidated Balance Sheet 16 Consolidated Statement of Changes in Equity 17 Consolidated Statement of Cash Flows 18 Notes to Condensed Cons |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 15, 2022 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| February 15, 2022 |
Execution Version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY ?[***]?, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND CUSTOMARILY AND ACTUALLY TREATED BY THE COMPANY AS PRIVATE OR CONFIDENTIAL. |
|
| February 15, 2022 |
World Leader In Eye Care $8.2B 90% 2021 sales Of visual impairment is preventable or treatable1 $400B+ 140+ Estimated annual costs of productivity loss associated with sight impairment2 Countries served by over 24,000 associates 100+ Pipeline products under development and 1,400+ associates working in R&D Note: Numbers are rounded for presentation purposes. 1 Source: The International Agency for t |
|
| February 15, 2022 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2021 Alcon Inc. |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring the shell company report Commission file number: 001-31269 Alcon Inc. |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 15, 2022 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| February 15, 2022 |
Change vs. 2021 actuals (cc)(2) EX-99.1 2 q42021pressrelease.htm EXHIBIT 99.1 - PRESS RELEASE Alcon Reports Fourth Quarter and Full Year 2021 Results •Fourth Quarter 2021 sales of $2.1 billion, up 11% or 13% constant currency •Full Year 2021 sales of $8.2 billion, up 22% or 20% constant currency •Above-market growth in both Surgical and Vision Care; sales momentum from key products, new product launches and commercial execution |
|
| February 15, 2022 |
Exhibit 12.1 Certification of CEO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David J. Endicott, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessar |
|
| February 15, 2022 |
Consent of PricewaterhouseCoopers LLP CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. |
|
| February 15, 2022 |
Amendment No. 1 to Option Agreement and Plan of Merger by and among Alcon Research, EXECUTION VERSION CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY ?[***]?, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND CUSTOMARILY AND ACTUALLY TREATED BY THE COMPANY AS PRIVATE OR CONFIDENTIAL. |
|
| February 10, 2022 |
CH:ALC / Alcon Inc / WCM INVESTMENT MANAGEMENT, LLC - FORM SC 13G/A Passive Investment SC 13G/A 1 formsc13ga.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alcon Inc (Name of Issuer) Common (Title of Class of Securities) H01301128 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 9, 2021 |
EX-99.2 3 q32021interimfinancialrepo.htm EX-99.2 ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 15 Consolidated Statement of Comprehensive Income/(Loss) 16 Consolidated Balance Sheet 17 Consolidated Statement of Changes in Equity 18 Consolidated S |
|
| November 9, 2021 |
Alcon Reports Third Quarter 2021 Results Alcon Reports Third Quarter 2021 Results ?Third quarter sales of $2.1 billion, up 15% or 14% constant currency ?Continued growth in all Surgical and Vision Care categories versus 2020, driven by innovation, commercial execution and market recovery ?Nine months cash from operations of $958 million and free cash flow of $578 million ?Expanding in surgical glaucoma with intended acquisition of Ivanti |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 9, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registra |
|
| November 8, 2021 |
Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio ?Expands Alcon?s leading surgical portfolio and leverages the company?s commercial execution expertise ?Strong safety and efficacy profile evidenced by five-year study on Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device ?Indicated to lower intraocular p |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 8, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701, Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registr |
|
| August 17, 2021 |
Alcon Reports Second Quarter 2021 Results EX-99.1 2 q22021pressrelease.htm EX-99.1 Alcon Reports Second Quarter 2021 Results •Second quarter sales of $2.1 billion, up 75% or 69% constant currency •Growth in all Surgical and Vision Care categories •First half cash from operations of $542 million and free cash flow of $320 million •Raises full year guidance: sales of $8.0 - $8.2 billion, core diluted EPS of $2.00 - $2.10 Ad Hoc Announcement |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 17, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registran |
|
| August 17, 2021 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 15 Consolidated Statement of Comprehensive Income/(Loss) 16 Consolidated Balance Sheet 17 Consolidated Statement of Changes in Equity 18 Consolidated Statement of Cash Flows 19 Notes to Condensed Cons |
|
| June 28, 2021 |
Alcon Announces Executive Committee Changes Alcon Announces Executive Committee Changes Geneva, June 28, 2021 ? Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced changes to its Executive Committee of Alcon (ECA). |
|
| June 28, 2021 |
6-K 1 form6-kx28jun2021.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 28, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by c |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 7, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant |
|
| June 7, 2021 |
Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021 ?18 abstracts accepted, underscoring Alcon?s commitment to vision, comfort and ocular surface health ?TOTAL30 designed with water gradient technology that has biomimetic properties that mimic the corneal surface and demonstrates exceptional comfort from day one to day 30 GENEVA ? June 7, 2021 ? Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will present new data on several of its latest innovations at the British Contact Lens Association (BCLA) 2021 Clinical Conference & Exhibition. |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Alcon Inc. (Exact name of the registrant as specified in its charter) Switzerland 001-31269 98-0205094 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of princ |
|
| May 21, 2021 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form Exhibit 1.01 Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2020 Overview This Conflict Minerals Report for Alcon Inc. and its consolidated subsidiaries covers calendar year 2020 and was prepared in accordance with Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Rule 13p-1 under the Securities Exchange Act of 1934 (collectively, th |
|
| May 4, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 4, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the reg |
|
| May 4, 2021 |
EX-99.2 3 q12021interimfinancialrepo.htm EX-99.2 ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 7 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 10 Consolidated Statement of Comprehensive Income/(Loss) 11 Consolidated Balance Sheet 12 Consolidated Statement of Changes in Equity 13 Consolidated St |
|
| May 4, 2021 |
Alcon Reports First Quarter 2021 Results Alcon Reports First Quarter 2021 Results ?First quarter sales of $1.9 billion, up 5% or 2% constant currency ?Strong commercial execution drives the global launch of new product innovations ?Substantially completes separation process ?Full year guidance: sales of $7.8 to $8.0 billion and core diluted EPS of $1.85 to $1.95 Geneva, May 4, 2021 - Alcon (SIX/NYSE:ALC), the global leader in eye care, r |
|
| April 28, 2021 |
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza ?Expands Alcon?s existing portfolio and strengthens position in the ophthalmic eye drops market ?Builds on company?s ophthalmic pharmaceutical manufacturing expertise Geneva, April 28, 2021 ? Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed |
|
| April 28, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 28, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the |
|
| March 25, 2021 |
Current Report of Foreign Issuer - 6-K 6-K 1 form6-kxagminvite.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 25, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Ind |
|
| March 25, 2021 |
IMPORTANT INFORMATION RELATING TO COVID-19 PANDEMIC IMPORTANT INFORMATION RELATING TO COVID-19 PANDEMIC Dear Shareholders, As a result of the continuing exceptional circumstances due to the coronavirus (COVID-19) pandemic, the 2021 Annual General Meeting will be held without the personal attendance of shareholders and you will not be granted access to the meeting room, in accordance with the Ordinance of the Swiss Federal Council regarding measures on combating the coronavirus (COVID-19) as amended on March 1, 2021 (COVID-19 Ordinance 3). |
|
| March 25, 2021 |
Alcon Publishes Agenda for Annual General Meeting EX-99.1 2 a991agmagendafinal.htm EX-99.1 Alcon Publishes Agenda for Annual General Meeting Geneva, March 24, 2021 – Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 28, 2021. As a result of the continuing exceptional circumstances due to the coronavirus (COVID-19) pandemic, the 2021 AGM will be held without the personal attendance of shareho |
|
| February 23, 2021 |
Consent of PricewaterhouseCoopers LLP CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. |
|
| February 23, 2021 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 10 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 14 Consolidated Statement of Comprehensive Income/(Loss) 15 Consolidated Balance Sheet 16 Consolidated Statement of Changes in Equity 17 Consolidated Statement of Cash Flows 18 Notes to Condensed Cons |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ? SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring the shell company report Commission file number: 001-31269 Alcon Inc. |
|
| February 23, 2021 |
Exhibit 12.1 Certification of CEO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David J. Endicott, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessar |
|
| February 23, 2021 |
Exhibit 12.2 Certification of CFO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Timothy C. Stonesifer, certify that: 1.I have reviewed this annual report on Form 20-F of Alcon Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece |
|
| February 23, 2021 |
Alcon Inc. UK Share Incentive Plan DATED 17/08/2020 (1)ALCON INC. (2)SOLIUM TRUSTEE (UK) LIMITED (REGISTERED NUMBER 09154605) TRUST DEED AND RULES OF THE ALCON INC. UK SHARE INCENTIVE PLAN Adopted by the Board of Directors of the Company on 9th April 2019 Registered with HM Revenue & Customs with scheme reference number XG1100000162916 Table of Contents Page 1. DEFINITIONS 1 2. TRUSTS OF THE PLAN 1 3. NOTICES TO PARTICIPANTS 2 4. I |
|
| February 23, 2021 |
Consent of PricewaterhouseCoopers SA EX-15.2 11 exhibit15220-f2020.htm EX-15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-230794) of Alcon Inc. of our report dated February 28, 2019 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers SA Geneva, Switzerland February 23, 2021 |
|
| February 23, 2021 |
Alcon Reports Fourth Quarter and Full Year 2020 Results EX-99.1 2 q42020pressrelease.htm EX-99.1 Alcon Reports Fourth Quarter and Full Year 2020 Results •Fourth quarter sales of $1.9 billion return to growth, up 2% or 1% constant currency •Continued recovery resulted in full year sales of $6.8 billion, 8% below last year •New product launches driving market share gains; executing on strategic initiatives •Generated $823 million in cash from operations |
|
| February 23, 2021 |
Exhibit 13.2 Certification of CFO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. ? 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the ?Company?) on Form 20-F for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (this ?Report?), full |
|
| February 23, 2021 |
Exhibit 13.1 Certification of CEO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. ? 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1)this annual report for Alcon Inc. (the ?Company?) on Form 20-F for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (this ?Report?), full |
|
| February 23, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 23, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether t |
|
| February 23, 2021 |
Articles of Incorporation of Alcon Inc., as amended EX-1.1 2 exhibit1120-f2020.htm EX-1.1 Articles of Incorporation of Alcon Inc. December 1, 2020 1 Articles of Incorporation of Alcon Inc. Section 1 Corporate Name, Registered Office, Purpose and Duration 2 Section 2 Share Capital 3 Section 3 Corporate Bodies 5 A. General Meeting of Shareholders 5 B. Board of Directors 10 C. Auditors 15 Section 4 Compensation of the Board of Directors and the Execut |
|
| February 23, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 23, 2021 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether t |
|
| February 23, 2021 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2020 Alcon Inc. |
|
| February 23, 2021 |
Regulations of the Board of Directors of Alcon Inc., as amended May 6, 2020 (English Translation) Regulations of the Board of Directors, its Committees and the Executive Committee of Alcon Inc. |
|
| February 23, 2021 |
2020 Annual Report See Brilliantly Four Things We Are Doing During COVID-19 Standing behind our associates Ensuring critical supply of our products Promoting the safe use of our products Staying committed to our core principles As the world faces a threat that cannot be seen, Alcon remains fully committed to serving the eye care professionals, patients and customers who depend on us. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Alcon Inc. (Name of Issuer) Common Stock (Title of Class of Securities) H01301128 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 10, 2020 |
Alcon Reports Third Quarter 2020 Results Alcon Reports Third Quarter 2020 Results ? Significant recovery in third quarter sales to $1. |
|
| November 10, 2020 |
Three months ended September 30 ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 11 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statement 15 Consolidated Statement of Comprehensive (Loss)/Income 16 Consolidated Balance Sheet 17 Consolidated Statement of Changes in Equity 18 Consolidated Statement of Cash Flows 19 Notes to Condensed Cons |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 10, 2020 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether t |
|
| August 18, 2020 |
Alcon Reports Second Quarter 2020 Results Alcon Reports Second Quarter 2020 Results • Second quarter sales of $1.2 billion, a decrease of 36%, or 34% constant currency • Sequential monthly improvements since April, driven by the global recovery • Continued progress on strategic initiatives and innovation roadmap • Successfully raised $750 million from senior notes to further strengthen liquidity Geneva, August 18, 2020 - Alcon (SIX/NYSE:A |
|
| August 18, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 18, 2020 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the |
|
| August 18, 2020 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 10 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statements 14 Consolidated Statements of Comprehensive (Loss)/Income 15 Consolidated Balance Sheets 16 Consolidated Statements of Changes in Equity 17 Consolidated Statements of Cash Flows 18 Notes to Condensed |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Alcon Inc. (Exact name of the registrant as specified in its charter) Switzerland 001-31269 98-0205094 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of princ |
|
| May 29, 2020 |
Report as required by Items 1.01 and 1.02 of this Form Exhibit 1.01 Conflict Minerals Report of Alcon Inc. For the Calendar Year Ended December 31, 2019 Overview This Conflict Minerals Report for Alcon Inc. and its consolidated subsidiaries covers calendar year 2019 and was prepared in accordance with Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Rule 13p-1 under the Securities Exchange Act of 1934 (collectively, th |
|
| May 18, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 18, 2020 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the re |
|
| May 18, 2020 |
Alcon prices US$750.0 million senior notes offering Alcon prices US$750.0 million senior notes offering GENEVA, May 18, 2020 ? Alcon (SIX/NYSE: ALC) announced that it has commenced and priced a private offering of US$750.0 million aggregate principal amount of its 2.600% senior notes due 2030 (the ?Notes?). The Notes will be issued by Alcon Finance Corporation, Alcon?s indirect subsidiary, and will be fully and unconditionally guaranteed on a senio |
|
| May 12, 2020 |
ALCON INC. INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Liquidity and Capital Resources 8 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statements 11 Consolidated Statements of Comprehensive (Loss)/Income 12 Consolidated Balance Sheets 13 Consolidated Statements of Changes in Equity 14 Consolidated Statements of Cash Flows 15 Notes to Condensed |
|
| May 12, 2020 |
Alcon Reports First Quarter 2020 Results Alcon Reports First Quarter 2020 Results ? Solid first quarter sales of $1.8 billion, an increase of 3%, or 4% constant currency ? Successful launch of PATADAY strengthens Alcon's leadership in the US OTC allergy market ? Decline in global demand for surgical procedures will negatively impact second quarter results ? Focus on associate safety, business continuity and financial flexibility Geneva, |
|
| May 12, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 12, 2020 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the re |
|
| May 6, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 6, 2020 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the reg |
|
| May 6, 2020 |
Alcon shareholders approve all proposed resolutions at the 2020 Annual General Meeting EX-99.1 2 a2019agmvotingresultspress.htm EXHIBIT 99.1 - 2020 AGM Alcon shareholders approve all proposed resolutions at the 2020 Annual General Meeting GENEVA, May 6, 2020 – Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced shareholder approval of all resolutions proposed at its 2020 Annual General Meeting. Given the global COVID |
|
| April 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 7, 2020 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the r |
|
| April 7, 2020 |
Alcon provides update on COVID-19 EX-99.1 2 pressrelease-covidx19.htm EXHIBIT 99.1 - ALCON PROVIDES UPDATE ON COVID-19 Alcon provides update on COVID-19 • Due to uncertainty around impact of COVID-19, previous 2020 guidance is withdrawn • In lieu of attendance at the Annual General Meeting, Alcon shareholders are directed to exercise voting rights exclusively via independent representative • To maintain financial flexibility, comp |
|
| February 25, 2020 |
Consent of PricewaterhouseCoopers LLP EX-15.1 10 exhibit151consentofpri.htm EXHIBIT 15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-230794) of Alcon Inc. of our report dated February 25, 2020 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers LLP Fort Worth, Te |
|
| February 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 25, 2020 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether t |
|
| February 25, 2020 |
Letter from PricewaterhouseCoopers SA EX-15.3 12 exhibit153letterfrompr.htm EXHIBIT 15.3 Exhibit 15.3 February 25, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Alcon Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 16F(a) of Form 20-F of Alcon Inc. dated February 25, 2020. We agree |
|
| February 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 25, 2020 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether t |
|
| February 25, 2020 |
Exhibit 12.1 Certification of CEO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David J. Endicott, certify that: 1. I have reviewed this annual report on Form 20-F of Alcon Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necess |
|
| February 25, 2020 |
Alcon Reports Full Year 2019 Results Alcon Reports Full Year 2019 Results ? 2019 net sales to third parties up 3%, or 5% constant currency (cc) ? Third consecutive year of top line growth ? Generated $920 million in cash from operations and free cash flow of $367 million ? Full year 2020 outlook: net sales growth of 5% to 6% (cc) and core EPS $1. |
|
| February 25, 2020 |
Alcon Inc. Long Term Incentive Plan Adopted on April 9, 2019 Amended on February 4, 2020 1 Alcon Inc. Long Term Incentive Plan Contents 1 DEFINITIONS AND INTERPRETATION 1 1.1 Definitions 1 1.2 Interpretation 7 2 PURPOSE OF THE PLAN 7 3 SHARES SUBJECT TO THE PLAN 7 3.1 Shares Subject to the Plan 7 3.2 Lapsed Awards 9 4 GRANTING OF AWARDS 9 4.1 Selection of Participants 9 4.2 Timing of Awards 9 4.3 |
|
| February 25, 2020 |
Consent of PricewaterhouseCoopers SA EX-15.2 11 exhibit152consentofpri.htm EXHIBIT 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-230794) of Alcon Inc. of our report dated February 28, 2019 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers SA Geneva, Switzerland February |
|
| February 25, 2020 |
Articles of Incorporation of Alcon Inc., as amended November 29, 2019 (English Translation) Exhibit 1.1 Articles of Incorporation of Alcon Inc. 1 | Articles of Incorporation of Alcon Inc. Section 1 Corporate Name, Registered Office, Purpose and Duration 2 Section 2 Share Capital 4 Section 3 Corporate Bodies 7 A. General Meeting of Shareholders 7 B. Board of Directors 13 C. Auditors 19 Section 4 Compensation of the Board of Directors and the Executive Committee 20 Section 5 Annual Financi |
|
| February 25, 2020 |
Exhibit 4.13 Alcon Inc. Deferred Bonus Stock Plan Adopted on April 9, 2019 Amended on February 4, 2020 1 TABLE OF CONTENTS 1Definitions and Interpretation 3 1.1Definitions 3 1.2Interpretation 4 2Purpose of the Plan 5 3Shares Subject to the Plan 5 3.1Shares Subject to the Plan 5 3.2Lapsed Awards 5 4Determination of Deferred Bonus Stock Awards 6 4.1STI Equity Awards 6 4.2Voluntary Deferral Awards 6 |
|
| February 25, 2020 |
Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2019 Alcon Inc. (?Alcon,? ?we,? ?us,? and ?our?) had the following securities registered pursuant to Section 12(b) of the Exchange Act: A. OFFER AND LISTING DETAILS Alcon is a stock corporation (Aktiengesellschaft) organized under the laws of Switzerland in accordance with article 620 et seq. o |
|
| February 25, 2020 |
Exhibit 12.2 Certification of CFO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Timothy C. Stonesifer, certify that: 1. I have reviewed this annual report on Form 20-F of Alcon Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact ne |
|
| February 25, 2020 |
1 | Alcon Annual Report 2019 2 | Alcon Annual Report 2019 Dear Shareholder, In 1945, two pharmacists in Fort Worth, Texas, Robert Alexander and William Conner, started a company that would focus on manufacturing and selling products in a relatively new and underserved market at the time: eye care. |
|
| February 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31269 Alcon Inc. |
|
| February 25, 2020 |
Exhibit 13.1 Certification of CEO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1) this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), ful |
|
| February 25, 2020 |
Exhibit 13.2 Certification of CFO Pursuant to 18 U.S.C. Section 1350 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that: (1) this annual report for Alcon Inc. (the “Company”) on Form 20-F for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), ful |
|
| November 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 19, 2019 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether t |
|
| November 19, 2019 |
Alcon Reports Third Quarter and Nine Months 2019 Results Alcon Reports Third Quarter and Nine Months 2019 Results • Third quarter sales of $1. |
|
| November 19, 2019 |
Three months ended September 30 ALCON INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statements 11 Consolidated Statements of Comprehensive (Loss)/Income 12 Consolidated Balance Sheets 13 Consolidated Statements of Changes in Equity 14 Consolidated Statements of Cash Flows 15 Notes to Condensed Consolidate |
|
| August 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 27, 2019 Commission File Number: 001-31269 ALCON INC (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the |
|
| August 27, 2019 |
MEDIA RELEASE · COMMUNIQUE AUX MEDIAS · MEDIENMITTEILUNG Exhibit 99.1 MEDIA RELEASE ? COMMUNIQUE AUX MEDIAS ? MEDIENMITTEILUNG Alcon Introduces AcrySof IQ PanOptix Trifocal IOL in the U.S., the First and Only FDA-Approved Trifocal Lens ? PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses1,2 ? More than ninety-nine percent of PanOptix patients in the FDA clinical study sai |
|
| August 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 20, 2019 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the |
|
| August 20, 2019 |
ALCON INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL REPORT INDEX Page Operating Performance 2 Condensed Consolidated Interim Financial Statements (unaudited) Consolidated Income Statements 11 Consolidated Statements of Comprehensive (Loss)/Income 12 Consolidated Balance Sheets 13 Consolidated Statements of Changes in Equity 14 Consolidated Statements of Cash Flows 15 Notes to Condensed Consolidate |
|
| August 20, 2019 |
Alcon Reports Second Quarter and First Half 2019 Results EX-99.1 2 q22019pressrelease.htm EXHIBIT 99.1 Alcon Reports Second Quarter and First Half 2019 Results • Second quarter sales of $1.9 billion, an increase of 2%, or 5% constant currency (cc) • Announced the launch of PRECISION1, a new daily SiHy lens designed for the mainstream market • Second quarter mid-single digit growth in all product categories (cc) • Reiterated full year outlook Geneva, Aug |
|
| May 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 16, 2019 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the re |
|
| May 16, 2019 |
Alcon Reports First Quarter 2019 Trading Update EX-99.1 2 a19-100261ex99d1.htm EX-99.1 Exhibit 99.1 Alcon Reports First Quarter 2019 Trading Update · First quarter sales of $1.8 billion, flat to last year; an increase of 4% constant currency (cc) · Healthy momentum in Surgical business, with 2% growth and 7% constant currency growth · Full year 2019 outlook of 3% to 5% constant currency net sales growth and 17% to 18% core operating margin Gene |
|
| April 10, 2019 |
Alcon Inc. Deferred Bonus Stock Plan EX-99.2 5 a19-79231ex99d2.htm EX-99.2 Exhibit 99.2 Alcon Inc. Deferred Bonus Stock Plan Adopted on April 9, 2019 Adopted by the Board of Directors of Alcon Inc. on April 9, 2019 and effective in relation to awards made on or after April 10, 2019. 1 Contents 1 DEFINITIONS AND INTERPRETATION 4 1.1 Definitions 4 1.2 Interpretation 5 2 PURPOSE OF THE PLAN 5 3.1 Shares Subject to the Plan 5 3.2 Lapsed |
|
| April 10, 2019 |
Alcon Inc. UK Share Incentive Plan and Forms of Agreement Thereunder EX-99.5 8 a19-79231ex99d5.htm EX-99.5 Exhibit 99.5 DATED 2019 (1) ALCON INC. (2) LINK MARKET SERVICES TRUSTEES LIMITED TRUST DEED AND RULES OF THE ALCON INC. UK SHARE INCENTIVE PLAN Adopted by the Board of Directors of the Company on 9th April 2019 Registered with HM Revenue & Customs with scheme reference number [insert scheme reference number] TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. TRUSTS OF |
|
| April 10, 2019 |
EX-99.4 7 a19-79231ex99d4.htm EX-99.4 Exhibit 99.4 ALCON LABORATORIES IRELAND SHARE PARTICIPATION SCHEME TRUST DEED & RULES TRUST DEED Title Page Number 1. Participating Company Contributions 4 2. Declaration of Trust 5 3. Distribution of trust funds 6 4. Appropriation of Scheme Shares 6 5. Maintenance of records 6 6. Participating Companies 7 7. Replacement of Company 7 8. Trustee liability and i |
|
| April 10, 2019 |
As filed with the Securities and Exchange Commission on April 10, 2019 As filed with the Securities and Exchange Commission on April 10, 2019 Registration No. |
|
| April 10, 2019 |
EX-99.3 6 a19-79231ex99d3.htm EX-99.3 Exhibit 99.3 Alcon Swiss Employee Share Ownership Plan (ESOP) Adopted on April 9, 2019 Adopted by the Board of Directors of Alcon Inc. on April 9, 2019, and effective in relation to awards made on or after April 10, 2019 Contents 1 Definitions and Interpretation 1 2 Purpose of the Plan 3 3 Shares Subject to the Plan 4 4 Entitlement to Participate 4 5 Payment o |
|
| April 10, 2019 |
Alcon Inc. Long Term Incentive Plan and Forms of Agreement Thereunder EX-99.1 4 a19-79231ex99d1.htm EX-99.1 Exhibit 99.1 Alcon Inc. Long Term Incentive Plan Adopted on April 9, 2019 Adopted by the Board of Directors of Alcon Inc. on April 9, 2019, and effective in relation to awards made on or after April 10, 2019 Contents 1 DEFINITIONS AND INTERPRETATION 1 1.1 Definitions 1 1.2 Interpretation 6 2 PURPOSE OF THE PLAN 7 3 SHARES SUBJECT TO THE PLAN 7 3.1 Shares Subje |
|
| April 9, 2019 |
Exhibit 99.2 EXECUTION VERSION TAX MATTERS AGREEMENT, dated as of April 8, 2019 (this ?Agreement?), between Novartis AG, an Aktiengesellschaft organized under the laws of Switzerland (?Novartis?), and Alcon Inc., an Aktiengesellschaft organized under the laws of Switzerland (?Alcon? and, together with Novartis, the ?Parties?). WHEREAS, pursuant to the Separation and Distribution Agreement, dated a |
|
| April 9, 2019 |
8 APRIL 2019 NOVARTIS AG ALCON INC. PATENT AND KNOW-HOW LICENSE AGREEMENT Exhibit 99.8 Execution Version 8 APRIL 2019 NOVARTIS AG ALCON INC. PATENT AND KNOW-HOW LICENSE AGREEMENT CONTENTS ARTICLE PAGE 1. DEFINITIONS 1 2. GRANT OF LICENSES 1 3. SUB-LICENSES 4 4. THIRD PARTY RESTRICTIONS 5 5. DURATION 6 6. DISCLAIMER OF WARRANTIES 6 7. OWNERSHIP AND MAINTENANCE 7 8. INFRINGEMENT 8 9. TERMINATION 10 10. LIMITATION OF LIABILITY 11 11. TAX 11 12. CONFIDENTIALITY 12 13. NOTIC |
|
| April 9, 2019 |
8 APRIL 2019 ALCON INC. NOVARTIS AG BRAND LICENSE AGREEMENT EX-99.10 11 a19-74901ex99d10.htm EX-99.10 Exhibit 99.10 8 APRIL 2019 ALCON INC. NOVARTIS AG BRAND LICENSE AGREEMENT CONTENTS CLAUSE PAGE 1. GRANT OF LICENSE 1 2. SUBLICENSES 2 3. DURATION 3 4. CONDITIONS OF USE OF LICENSED IP RIGHTS 3 5. CONDITIONS OF USE OF TRANSITIONALLY LICENSED IP RIGHTS 5 6. MAINTENANCE OF LICENSED TMS 6 7. APPROVAL AND INSPECTION 7 8. OWNERSHIP OF LICENSED IP RIGHTS 8 9. INF |
|
| April 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Report on Form 6-K dated April 9, 2019 (Commission File No. 001-31269) Alcon Inc. (Name of Registrant) Rue Louis-d?Affry 6 1701 Fribourg Switzerland (Address of Principal Executive Offices) Indicate by check mark |
|
| April 9, 2019 |
8 APRIL 2019 NOVARTIS AG ALCON INC. BRAND LICENSE AGREEMENT Exhibit 99.9 Execution Version 8 APRIL 2019 NOVARTIS AG ALCON INC. BRAND LICENSE AGREEMENT CONTENTS CLAUSE PAGE 1. GRANT OF LICENSE 1 2. SUBLICENSES 2 3. DURATION 3 4. CONDITIONS OF USE OF LICENSED IP RIGHTS 3 5. CONDITIONS OF USE OF TRANSITIONALLY LICENSED IP RIGHTS 5 6. MAINTENANCE OF LICENSED TMS 7 7. APPROVAL AND INSPECTION 8 8. OWNERSHIP OF LICENSED IP RIGHTS 8 9. INFRINGEMENT 8 10. TERMINATI |
|
| April 9, 2019 |
Exhibit 99.4 Execution Copy DATED 8 APRIL 2019 NOVARTIS PHARMA AG and ALCON INC. MANUFACTURING AND SUPPLY AGREEMENT relating to the separation of the Alcon surgical and vision care business Puurs/Barcelona/Brazil MANUFACTURING AND SUPPLY AGREEMENT Page 1. DEFINITIONS AND INTERPRETATION 1 2. MANUFACTURE AND SUPPLY 21 3. FORECASTS AND ORDERS ? PUSH/PULL 25 4. CAPACITY BASELINE AND GATING PLAN 29 5. |
|
| April 9, 2019 |
8 APRIL 2019 NOVARTIS AG ALCON INC. PATENT AND KNOW-HOW LICENSE AGREEMENT EX-99.7 8 a19-74901ex99d7.htm EX-99.7 Exhibit 99.7 Execution Version 8 APRIL 2019 NOVARTIS AG ALCON INC. PATENT AND KNOW-HOW LICENSE AGREEMENT CONTENTS ARTICLE PAGE 1. DEFINITIONS 1 2. GRANT OF LICENSES 1 3. SUB-LICENSES 3 4. THIRD PARTY RESTRICTIONS 4 5. DURATION 6 6. DISCLAIMER OF WARRANTIES 6 7. OWNERSHIP AND MAINTENANCE 6 8. INFRINGEMENT 8 9. TERMINATION 9 10. LIMITATION OF LIABILITY 11 11. TA |
|
| April 9, 2019 |
8 APRIL 2019 NOVARTIS AG ALCON INC. TRANSITIONAL SERVICES AGREEMENT Exhibit 99.6 8 APRIL 2019 NOVARTIS AG ALCON INC. TRANSITIONAL SERVICES AGREEMENT Table of Contents 1. Relationship Management 1 2. Integration 3 3. Provision of Services 8 4. Separation and Information Technology Risk Control 10 5. General Obligations 14 6. Dependencies 16 7. Third Party Suppliers 16 8. Shared Premises 19 9. Record Keeping 19 10. Compliance with Laws 20 11. Intellectual Property R |
|
| April 9, 2019 |
Exhibit 99.5 Execution Copy DATED 8 APRIL 2019 NOVARTIS PHARMA AG and ALCON INC. MANUFACTURING AND SUPPLY AGREEMENT relating to the separation of the Alcon surgical and vision care business Aspex/Fort Worth/Singapore MANUFACTURING AND SUPPLY AGREEMENT Page 1. DEFINITIONS AND INTERPRETATION 1 2. MANUFACTURE AND SUPPLY 19 3. FORECASTS AND ORDERS 23 4. CAPACITY BASELINE AND GATING PLAN 26 5. TOLL MAN |
|
| April 9, 2019 |
8 APRIL 2019 NOVARTIS AG ALCON INC. EMPLOYEE MATTERS AGREEMENT Exhibit 99.3 8 APRIL 2019 NOVARTIS AG ALCON INC. EMPLOYEE MATTERS AGREEMENT CONTENTS Clause Page 1. ALCON EMPLOYEES 3 2. EMPLOYMENT LIABILITIES 7 3. LONG-TERM ASSIGNEES 9 4. CASH BONUS 9 5. PROTECTION OF TERMS AND CONDITIONS 10 6. COMPENSATION REVIEW 12 7. SHARE-BASED INCENTIVE SCHEMES 12 8. CERTAIN US EMPLOYEE BENEFIT MATTERS 17 9. BOOKS AND RECORDS 18 10. RESTRICTIVE COVENANTS 18 11. STAND-ALONE |
|
| April 9, 2019 |
8 APRIL 2019 NOVARTIS AG ALCON INC. SEPARATION AND DISTRIBUTION AGREEMENT EX-99.1 2 a19-74901ex99d1.htm EX-99.1 Exhibit 99.1 8 APRIL 2019 NOVARTIS AG ALCON INC. SEPARATION AND DISTRIBUTION AGREEMENT CONTENTS Clause Page 1. THE SEPARATION 3 2. THE ALCON TRANSFERRING ASSETS 5 3. THE NOVARTIS TRANSFERRING ASSETS 7 4. LOCAL SEPARATION AGREEMENTS 8 5. THE DISTRIBUTION 9 6. GLOBAL CONDITIONS 10 7. BRAZIL 12 8. TRANSFERRING CONTRACTS 12 9. MATTERS GOVERNED EXCLUSIVELY BY ANCIL |
|
| April 2, 2019 |
MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG Exhibit 99.1 6201 South Freeway Fort Worth, Texas 76134-2099 http://www.alcon.com MEDIA RELEASE ? COMMUNIQUE AUX MEDIAS ? MEDIENMITTEILUNG Alcon Announces Timothy Stonesifer as Chief Financial Officer Fort Worth, Texas, April 2, 2019 ? Alcon, the global leader in eye care and a division of Novartis, announced today that Timothy C. Stonesifer (?Tim?) will join the company as its new Senior Vice Pre |
|
| April 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2, 2019 Commission File Number: 001-31269 ALCON INC. (Registrant Name) Rue Louis-d?Affry 6 1701 Fribourg, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant |
|
| March 22, 2019 |
Exhibit 15.1 Alcon Inc. Rue Louis-d?Affry 6 CH-1701 Fribourg Switzerland Zurich, 21 March 2019 Form 20-F Registration Statement Dear Sir or Madam, We have been asked to issue a legal opinion letter as special Swiss legal counsel of Alcon Inc., Rue Louis-d?Affry 6, CH-1701 Fribourg, Switzerland, Swiss business identification number CHE-234.781.164 (the ?Company?), a stock corporation (Aktiengesells |
|
| March 22, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 22, 2019 |
March 22, 2019 VIA EDGAR AND ELECTRONIC MAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 22, 2019 |
Exhibit 15.2 March 21, 2019 Tax Opinion Regarding the Distribution of Alcon Inc. Ladies and Gentlemen: We have acted as counsel for Novartis AG, an Aktiengesellschaft organized under the laws of Switzerland (?Novartis?), in connection with the distribution of all of the stock of Alcon Inc., an Aktiengesellschaft organized under the laws of Switzerland (?Alcon?), held by Novartis to holders of Nova |
|
| March 22, 2019 |
Consent of PricewaterhouseCoopers SA Exhibit 15.4 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use in this Registration Statement on Form 20-F of Alcon Inc. of our report dated February 28, 2019 relating to the financial statements of the Novartis AG Alcon business, which appears in this Registration Statement. We also consent to the reference to us under the heading “Statements by Experts” in suc |
|
| March 21, 2019 |
Alcon Inc. Amendment No. 4 to Form 20-F Filed February 28, 2019 File No. 001-31269 March 21, 2019 Alcon Inc. Amendment No. 4 to Form 20-F Filed February 28, 2019 File No. 001-31269 Dear Ms. Percival: Alcon Inc. (the ?Company?) has today submitted with the U.S. Securities and Exchange Commission (the ?SEC?), via EDGAR, this letter and Amendment No. 6 (?Amendment No. 6?) to its draft Registration Statement on Form 20-F first submitted to the SEC on November 13, 2018 (the ?Registra |
|
| March 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 5 to FORM 20-F QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 13, 2019 |
Form of Regulations of the Board of Directors of Alcon Inc. Exhibit 1.2 Regulations of the Board of Directors, its Committees and the Executive Committee of Alcon Inc. (R?glement d?organisation d?Alcon Inc.) Alcon Inc. 1701 Fribourg, Switzerland Table of Contents Regulations of the Board of Directors, its Committees and the Executive Committee of Alcon Inc. 3 1 Section 1 General Provisions 4 Section 2 Board of Directors 7 Section 3 Committees of the Board |
|
| March 13, 2019 |
Form of Employee Matters Agreement by and between Novartis AG and Alcon Inc. Exhibit 4.3 2019 NOVARTIS AG ALCON INC. EMPLOYEE MATTERS AGREEMENT CONTENTS Clause Page 1. ALCON EMPLOYEES 3 2. EMPLOYMENT LIABILITIES 7 3. LONG-TERM ASSIGNEES 9 4. CASH BONUS 10 5. PROTECTION OF TERMS AND CONDITIONS 10 6. COMPENSATION REVIEW 12 7. SHARE-BASED INCENTIVE SCHEMES 12 8. CERTAIN US EMPLOYEE BENEFIT MATTERS 17 9. BOOKS AND RECORDS 18 10. RESTRICTIVE COVENANTS 18 11. STAND-ALONE EB ARRA |
|
| March 13, 2019 |
Exhibit 4.11 EXECUTION VERSION U.S.$3,800,000,000 and ?350,000,000 FACILITIES AGREEMENT dated 6 March 2019 for ALCON INC. arranged by BANK OF AMERICA MERRILL LYNCH INTERNATIONAL DESIGNATED ACTIVITY COMPANY, BNP PARIBAS FORTIS SA/NV, CITIGROUP GLOBAL MARKETS LIMITED, MORGAN STANLEY BANK INTERNATIONAL LIMITED and UBS AG, LONDON BRANCH with CITIBANK EUROPE PLC, UK BRANCH acting as Agent Ref: L-280014 |
|
| February 28, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 28, 2019 |
Pertinent pages from 2018 Annual Report of Novartis AG Exhibit 15.8 I...?...?...: I'I.,.... .....'..I..I .f 1 :".;,?..? ? . ..,.?.:... ?:; ,'f:? Item 6. Directors, Senior Management and Employees Executive Committee compensation philosophy and principles Novartis compensation philosophy Our compensation philosophy aims to ensure that Exec-utive Committee members are rewarded according to their success in implementing the Company strategy, and their co |
|
| February 28, 2019 |
Form of Separation and Distribution Agreement by and between Novartis AG and Alcon Inc. Exhibit 4.1 2019 NOVARTIS AG ALCON INC. SEPARATION AND DISTRIBUTION AGREEMENT CONTENTS Clause Page 1. THE SEPARATION 3 2. THE ALCON TRANSFERRING ASSETS 5 3. THE NOVARTIS TRANSFERRING ASSETS 7 4. LOCAL SEPARATION AGREEMENTS 8 5. THE DISTRIBUTION 9 6. GLOBAL CONDITIONS 10 7. BRAZIL 11 8. TRANSFERRING CONTRACTS 11 9. MATTERS GOVERNED EXCLUSIVELY BY ANCILLARY AGREEMENTS 12 10. INTERCOMPANY ARRANGEMENT |
|
| February 28, 2019 |
Form of Transitional Services Agreement by and between Novartis AG and Alcon Inc. Exhibit 4.6 2019 NOVARTIS AG ALCON INC. TRANSITIONAL SERVICES AGREEMENT Table of Contents 1. Relationship Management 1 2. Integration 3 3. Provision of Services 7 4. Separation and Information Technology Risk Control 10 5. General Obligations 14 6. Dependencies 15 7. Third Party Suppliers 16 8. Shared Premises 19 9. Record Keeping 19 10. Compliance with Laws 20 11. Intellectual Property Rights 20 |
|
| February 28, 2019 |
Consent of PricewaterhouseCoopers SA Exhibit 15.4 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use in this Registration Statement on Form 20-F of Alcon Inc. of our report dated February 28, 2019 relating to the financial statements of the Novartis AG Alcon business, which appears in this Registration Statement. We also consent to the reference to us under the heading ?Statements by Experts? in suc |
|
| February 28, 2019 |
Alcon Inc. Amendment No. 1 to Form 20-F Filed December 27, 2018 File No. 001-31269 February 28, 2019 Alcon Inc. Amendment No. 1 to Form 20-F Filed December 27, 2018 File No. 001-31269 Dear Ms. Percival: Alcon Inc. (the ?Company?) has today submitted with the U.S. Securities and Exchange Commission (the ?SEC?), via EDGAR, this letter and Amendment No. 4 (?Amendment No. 4?) to its draft Registration Statement on Form 20-F first submitted to the SEC on November 13, 2018 (the ?Regis |
|
| February 28, 2019 |
Form of Brand License Agreement by Alcon Inc. for the benefit of Novartis AG Exhibit 4.10 2019 ALCON INC. NOVARTIS AG BRAND LICENSE AGREEMENT CONTENTS CLAUSE PAGE 1. Grant of License 1 2. Sublicenses 2 3. Duration 3 4. Conditions of use of Licensed IP Rights 3 5. Conditions of use of Transitionally Licensed IP Rights 5 6. Maintenance of Licensed TMs 6 7. Approval and Inspection 7 8. Ownership of Licensed IP Rights 8 9. Infringement 8 10. Termination 10 11. Limitation of li |
|
| February 28, 2019 |
Form of Brand License Agreement by Novartis AG for the benefit of Alcon Inc. Exhibit 4.9 2019 NOVARTIS AG ALCON INC. BRAND LICENSE AGREEMENT CONTENTS CLAUSE PAGE 1. Grant of License 1 2. Sublicenses 2 3. Duration 3 4. Conditions of use of Licensed IP Rights 3 5. Conditions of use of Transitionally Licensed IP Rights 5 6. Maintenance of Licensed TMs 7 7. Approval and Inspection 7 8. Ownership of Licensed IP Rights 8 9. Infringement 8 10. Termination 10 11. Limitation of lia |
|
| February 28, 2019 |
Form of Patent and Know-How License Agreement by Alcon Inc. for the benefit of Novartis AG Exhibit 4.8 2019 NOVARTIS AG ALCON INC. PATENT AND KNOW-HOW LICENSE AGREEMENT CONTENTS ARTICLE Page 1. Definitions 1 2. Grant of Licenses 1 3. Sub-licenses 4 4. Third Party Restrictions 5 5. Duration 6 6. Disclaimer of Warranties 6 7. Ownership and Maintenance 7 8. Infringement 8 9. Termination 10 10. Limitation of liability 11 11. Tax 11 12. Confidentiality 12 13. Notices 12 14. Dispute Resolutio |
|
| February 28, 2019 |
Form of Patent and Know-How License Agreement by Novartis AG for the benefit of Alcon Inc. Exhibit 4.7 2019 NOVARTIS AG ALCON INC. PATENT AND KNOW-HOW LICENSE AGREEMENT CONTENTS ARTICLE PAGE 1. Definitions 1 2. Grant of Licenses 1 3. Sub-licenses 3 4. Third Party Restrictions 4 5. Duration 6 6. Disclaimer of Warranties 6 7. Ownership and Maintenance 6 8. Infringement 8 9. Termination 9 10. Limitation of liability 11 11. Tax 11 12. Confidentiality 11 13. Notices 12 14. Dispute Resolution |
|
| February 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to FORM 20-F QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 7, 2019 |
Articles of Incorporation of Alcon Inc., as amended January 29, 2019 (English Translation)† Exhibit 1.1 Articles of Incorporation of Alcon Inc. 29 January 2019 Section 1 Corporate Name, Registered Office, Purpose and Duration 2 Section 2 Share Capital 3 Section 3 Corporate Bodies 5 A. General Meeting of Shareholders 5 B. Board of Directors 8 C. Auditors 12 Section 4 Compensation of the Board of Directors and the Executive Committee 12 Section 5 Annual Financial Statements, Consolidated F |
|
| January 18, 2019 |
Form of Patent and Know-How License Agreement by Novartis AG for the benefit of Alcon lnc.† Exhibit 4.7 2019 NOVARTIS AG ALCON INC. PATENT AND KNOW-HOW LICENSE AGREEMENT CONTENTS ARTICLE PAGE 1. Definitions 1 2. Grant of Licenses 1 3. Sub-licenses 3 4. Third Party Restrictions 4 5. Duration 6 6. Disclaimer of Warranties 6 7. Ownership and Maintenance 6 8. Infringement 8 9. Termination 9 10. Limitation of liability 10 11. Tax 11 12. Confidentiality 11 13. Notices 12 14. Dispute Resolution |
|
| January 18, 2019 |
Form of Transitional Services Agreement by and between Novartis AG and Alcon Inc.† Exhibit 4.6 2019 NOVARTIS AG ALCON INC. TRANSITIONAL SERVICES AGREEMENT Table of Contents 1. Relationship Management 1 2. Integration 3 3. Provision of Services 7 4. Separation and Information Technology Risk Control 10 5. General Obligations 14 6. Dependencies 15 7. Third Party Suppliers 16 8. Shared Premises 19 9. Record Keeping 19 10. Compliance with Laws 20 11. Intellectual Property Rights 20 |
|
| January 18, 2019 |
Form of Reverse Manufacturing and Supply Agreement by and between Novartis Pharma AG and Alcon Inc.† Exhibit 4.5 DATED 2019 NOVARTIS PHARMA AG and ALCON INC. MANUFACTURING AND SUPPLY AGREEMENT relating to the separation of the Alcon surgical and vision care business Aspex/Fort Worth/Singapore 1 MANUFACTURING AND SUPPLY AGREEMENT Page 1. DEFINITIONS AND INTERPRETATION 1 2. MANUFACTURE AND SUPPLY 21 3. FORECASTS AND ORDERS 24 4. CAPACITY BASELINE AND GATING PLAN 28 5. TOLL MANUFACTURE 33 6. PRODUCT |
